Kyowa Hakko Kirin gears up to test IDO/PD-1 combo; AbbVie fights Humira biosimilars with 80% price cut in Europe

→ Turns out IDO is not dead yet. Kyowa Hakko Kirin has announced that it is testing its IDO inhibitor in combination with the PD-1 drug from Merck KGaA and Pfizer, avelumab. The Japanese pharma will take charge of the proof-of-concept trial in the US, which will recruit patients with solid tumors.

→ In an effort to dissipate the threat of Humira biosimilars, at least four of which launched in the EU last month, AbbVie has slashed the blockbuster rheumatoid arthritis drug’s price by 80% in European markets. That’s according to a new report from Bernstein’s Ronny Gal cited by multiple sources. Gal suggests that AbbVie’s goal here is to “defend the US market by denying the biosimilars in-market experience,” though they will still be able to make money at this price.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->